Silo Pharma Submits Pre-Investigational NDA To FDA For SPC-15 As A Treatment For PTSD And Anxiety
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma, Inc. (NASDAQ:SILO) has submitted a pre-Investigational New Drug (pre-IND) briefing package and meeting request to the FDA for SPC-15, an intranasal treatment for PTSD and anxiety. This marks a significant step in the clinical development of their novel therapeutic.
June 04, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silo Pharma has submitted a pre-IND briefing package to the FDA for SPC-15, an intranasal treatment for PTSD and anxiety. This is a significant milestone in their clinical development process.
The submission of a pre-IND package to the FDA is a critical step in the drug development process, indicating progress and potential future approval. This news is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100